TBPH
Theravance Biopharma, Inc.17.53
-0.24-1.35%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
888.29MP/E (TTM)
30.75Basic EPS (TTM)
0.57Dividend Yield
0%Recent Filings
10-K
FY2025 results
Theravance Biopharma posted FY2025 net income of $105.9 million, fueled by a $75.1 million net gain from selling TRELEGY royalties to GSK for $225 million in June and $50 million TRELEGY milestone income, while YUPELRI net sales hit launch-to-date highs with 12% y/y growth to $266.6 million (implied 35% share: $93.3 million, up 12%) driven by 7% customer demand gains and better pricing. Operating expenses held flat at $111.1 million as R&D wrapped CYPRESS enrollment in August, yet Q4 momentum faltered with ampreloxetine's Phase 3 miss announced March 2026, prompting R&D wind-down. Cash swelled to $326.5 million. Restructuring eyes 60% op-ex cut to $70 million run-rate by Q3 2026. Generic YUPELRI challenges loom.
8-K
Restructuring unlocks $60-70M cash flow
Theravance Biopharma reported Q4 and full-year 2025 results, with YUPELRI net sales hitting $266.6 million (up 12% YoY) triggering a $25 million milestone, and TRELEGY sales of $3.9 billion (up 12% YoY) unlocking $50 million. Restructuring post-CYPRESS flop will slash op-ex 60%, yielding $60-70 million annualized cash flow from Q3 2026; ~$400 million cash expected end-Q1. Strategic Review Committee accelerates value-maximizing options like sale.
8-K
CYPRESS fails; cuts 50% staff.
Theravance Biopharma's Phase 3 CYPRESS study flopped on its primary endpoint, killing the ampreloxetine program. Restructuring axes 50% of staff, slashing costs 60% ($70M savings) over two quarters at $5-7M severance hit. Cash hits $400M by Q1 2026 end. YUPELRI fuels $60-70M annual cash flow. Strategic review accelerates.
8-K
CYPRESS topline Q1 2026
Theravance Biopharma furnished its January 2026 corporate presentation under Regulation FD ahead of San Francisco investor meetings January 12-15. It spotlights the pivotal CYPRESS Phase 3 trial for ampreloxetine in symptomatic nOH due to MSA, with topline data due Q1 2026 after completing enrollment. Cash sits at $333M with no debt; YUPELRI drove Q3 2025 breakeven. Data readout looms large.
8-K
Ampreloxetine KOL event held
APLS
Apellis Pharmaceuticals, Inc.
25.31+0.75
AUPH
Aurinia Pharmaceuticals Inc
15.85+0.16
BMRN
BioMarin Pharmaceutical Inc.
51.77-0.35
INVA
Innoviva, Inc.
19.92-0.22
LQDA
Liquidia Corporation
35.26+1.07
RVPH
Reviva Pharmaceuticals Holdings
0.64+0.01
TRVI
Trevi Therapeutics, Inc.
12.41-0.20
UPB
Upstream Bio, Inc.
29.32+2.12
UTHR
United Therapeutics Corporation
500.00-0.30
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05